ArticleBiologia futura2021
Interactions between probiotic and oral pathogenic strains.
Article in Biologia futura, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06063239 (Probiotics in Special Needs Patients at High Risk for Tooth Decay), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Probiotics in Special Needs Patients at High Risk for Tooth Decay: a Randomized Controlled Trial.
Who cites it
12 citing papers in PubMed.
- Trial
- Analysis of oral microbiome characteristics and their correlation with oral health diseases.Medicine · 2026Article
- Combination of Lacticaseibacillus rhamnosus and Weissella confusa treatment improves ligature-induced periodontitis in rats via immune modulation and inhibition of oral pathogens.BMC oral health · 2026Article
- Oral Administration of Freeze-DriedFood science & nutrition · 2026Article
- Clinical and Microbiological Changes Following Multi-Strain Probiotic Mouthrinse Use in Dental Students with Halitosis: A Prospective Single-Arm Study.Clinical, cosmetic and investigational dentistry · 2026Article
- Sweet Orange Juice Processing By-Product Extracts: A Caries Management Alternative to Chlorhexidine.Biomolecules · 2023Article
- Mechanism of Action ofAntibiotics (Basel, Switzerland) · 2023Article
- Bioinformatic and literature assessment of toxicity and allergenicity of a CRISPR-Cas9 engineered gene drive to control Anopheles gambiae the mosquito vector of human malaria.Malaria journal · 2023Article
- Growth Conditions InfluenceBiomedicines · 2023Article
- In Vitro Selection ofInternational journal of molecular sciences · 2022Article
- Theoretical Study at the Molecular Mechanics Level of the Interaction of Tetracycline and Chloramphenicol with the Antibiotic Receptors Present inAntibiotics (Basel, Switzerland) · 2022Article
- Complete Genome Sequence ofMicrobiology resource announcements · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
More than 6 billion bacteria and other microorganisms live in the adult oral cavity. As a result of any deleterious effect on this community, some microorganisms will survive better than others, which may trigger pathogenic processes like caries, halitosis, gingivitis or periodontitis. Oral dysbiosis is among the most frequent human health hazards globally. Quality of life of patients deteriorates notably, while treatments are often unpleasant, expensive and irreversible, e.g. tooth loss. In the experiments reported here, we investigated the individual interactions between 8 pathogenic and 8 probiotic strains and a commercially available probiotic product. Almost all pathogens, namely Fusobacterium nucleatum, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Streptococcus mutans, Streptococcus oralis, Streptococcus gordonii, Enterococcus faecalis and Prevotella buccae are pathogens frequently occurring in the oral cavity. The used probiotic strains were Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus delbrueckii, Bifidobacterium thermophilum and two Streptococcus dentisani isolates. Using a modified agar diffusion method, we investigated capability of the probiotic bacteria to prevent the growth of the pathogenic ones in order to identify candidates for future therapeutic treatments. The results indicated successful bacteriocin production, i.e. growth inhibition, against every pathogenic bacterium by at least 5 probiotic strains.
Indexed as
Identifiers
34554489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.